CEO and CFO Exercise of Options and RPT

Eco Animal Health Group PLC

19 August 2026

19 August 2026

ECO Animal Health Group plc

("ECO" or the "Company")

CEO and CFO Exercise of Share Options and Director/PDMR Shareholdings

Related Party Transaction

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that David Hallas, Chief Executive Officer, and Christopher Wilks, Chief Financial Officer, have respectively exercised 7,333 and 5,649 nominal cost share options granted under the Company's Long Term Incentive Plan ("LTIP"). These share options were granted on 24 February 2023. The remainder of the share options awarded to Executive Directors on this date lapsed as the performance conditions were not met.  Accordingly, there are no further vested but unexercised share options related to the February 2023 grant to Executive Directors.

The exercises have been fully satisfied through the transfer of existing ordinary shares held by the ECO Animal Health Group Employee Benefit Trust ("EBT"). No new ordinary shares have been issued in connection with these transactions.

Following this, David Hallas holds 232,720 ordinary shares, representing approximately 0.34 per cent. of the Company's issued share capital and Chris Wilks holds 183,835 ordinary shares, representing approximately 0.27 per cent.

Therefore, the total number of ordinary shares with voting rights in the Company remains at 67,759,671. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The notifications below, provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details.

Related Party Transaction

The Company announced on 12 August 2026 that it had signed a perpetual exclusive licence agreement with Vaxinano SAS, a biotechnology company pioneering the development of prophylactic and therapeutic vaccines, for Vaxinano's sheep vaccine candidate against toxoplasmosis (the "Agreement").

The Company initially agreed heads of terms with Vaxinano in April 2026, with ECO board approval for the Agreement granted in July ahead of signing in August.

Dr. Joachim Hasenmaier, Non-Executive Chairman of ECO, is also a board member of Vaxinano and thus Vaxinano is deemed to be a related party of the Company under the amended definition of 'related party' in the AIM Rules for Companies that came into effect on 5 August 2026 (the "2026 AIM Rules"). Accordingly, and on the basis of the profits test which has determined the disclosure requirements, the Agreement is deemed to be a related party transaction under AIM Rule 13 of the 2026 AIM Rules. The directors of the Company (excluding Dr. Joachim Hasenmaier), having consulted with the Company's Nominated Adviser, consider that the terms of the Agreement are fair and reasonable insofar as the Company's shareholders are concerned.

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group's proprietary lead product, Aivlosin^® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN^® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group's website or LinkedIn page for further information.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	David Hallas
2.	Reason for the notification
a.	Position/status	Chief Executive Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP7OB55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Exercise of options over ordinary shares of 5p each.
c.	Price(s) and volume(s)	Price(s) Volume(s) 5p 7,333
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	19 August 2026
f.	Place of the transaction	Off market

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Chris Wilks
2.	Reason for the notification
a.	Position/status	Chief Financial Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP7OB55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Exercise of options over ordinary shares of 5p each.
c.	Price(s) and volume(s)	Price(s) Volume(s) 5p 5,649
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	19 August 2026
f.	Place of the transaction	Off market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.